Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 5/20 | 0.60 |
| ▸ | KIF11 | P52732 | 6/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3378781 | 0.89 | KIF11 (0.68) | CYP17A1KIF11NR3C1AR | |
| SCHEMBL3372908 | 0.84 | KIF11 (0.68) | CYP17A1KIF11NR3C1ARFFAR4 | |
| SCHEMBL4661111 | 0.80 | CYP17A1 (0.56) | CYP17A1KIF11KDM4EALDH1A1LMNA | |
| SCHEMBL3375785 | 0.80 | KIF11 (0.59) | CYP17A1KIF11NR3C1ARAKR1C3 | |
| SCHEMBL15220225 | 0.79 | CYP17A1 (0.60) | CYP17A1KIF11FFAR4 | |
| SCHEMBL4662605 | 0.77 | KIF11 (0.68) | CYP17A1KIF11MAPT | |
| SCHEMBL19323000 | 0.76 | AKR1C3 (0.58) | ARAKR1C3AKR1C2ALDH1A1HPGD | |
| SCHEMBL3378380 | 0.76 | KIF11 (0.53) | CYP17A1KIF11NR3C1ARFFAR4 | |
| SCHEMBL21180017 | 0.75 | CYP17A1 (0.59) | CYP17A1NR3C1 | |
| SCHEMBL3374437 | 0.75 | RORC (0.57) | CYP17A1KIF11NR3C1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694281-A4 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2008-12-24 | — | — | EP | claimed |
| US-20070259951-A1 | Compounds, Compositions and Methods | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | US | claimed |
| EP-1694281-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-30 | — | — | EP | claimed |
| WO-2005060692-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-07 | — | — | WO | claimed |
| EP-1694281-A4 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070259951-A1 | Compounds, Compositions and Methods | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | US | disclosed |
| EP-1694281-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005060692-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259951-A1 | Compounds, Compositions and Methods | ALPP, PCNA, MKI67 | CYP17A1 250/4885KIF11 824/4885NR3C1 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.